Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
JOP ; 14(5): 515-20, 2013 Sep 10.
Artículo en Inglés | MEDLINE | ID: mdl-24018598

RESUMEN

CONTEXT: Pancreatic cancer is frequently complicated by malignancies in other organs. However, synchronous triple cancers including pancreatic cancer have been seldom reported in the English language literature. CASE REPORT: We describe the rare case of a 77-year-old man with triple cancers of the pancreas, stomach, and cecum. Biopsies revealed that all three tumors were adenocarcinomas. The pancreatic and gastric tumors were positive for cytokeratin 7 and negative for cytokeratin 20, whereas the cecal tumor was negative for cytokeratin 7 and positive for cytokeratin 20. K-ras mutations were present at codon 12 in the pancreatic tumor and at codon 13 in the cecal tumor, but were absent from the gastric tumor. Since the three tumors had different characteristics, the patient was diagnosed with synchronous triple cancers. Because invasive surgery was required to remove all three tumors and the patient had risk factors for surgery, we elected to treat him with chemotherapy. All three cancers were markedly reduced in size by treatment with cycles of 100 mg/day S-1 for 2 weeks, followed by a 1-week rest. The patient later developed hypoproteinemia and anasarca, which was diagnosed as pancreatic exocrine insufficiency due to pancreatic head cancer. Treatment with pancrelipase resulted in dramatic improvements in hypoproteinemia and anasarca. CONCLUSIONS: This is the first case report in which S-1 was effective in triple cancers of the pancreas, stomach, and cecum. Patients with pancreatic head cancer should be monitored for pancreatic exocrine insufficiency.


Asunto(s)
Neoplasias del Ciego/tratamiento farmacológico , Neoplasias Primarias Múltiples/tratamiento farmacológico , Ácido Oxónico/uso terapéutico , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Gástricas/tratamiento farmacológico , Tegafur/uso terapéutico , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/genética , Adenocarcinoma/metabolismo , Anciano , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Neoplasias del Ciego/genética , Neoplasias del Ciego/metabolismo , Combinación de Medicamentos , Edema/inducido químicamente , Edema/tratamiento farmacológico , Humanos , Hipoproteinemia/inducido químicamente , Hipoproteinemia/tratamiento farmacológico , Queratina-20/análisis , Queratina-7/análisis , Masculino , Mutación , Neoplasias Primarias Múltiples/genética , Neoplasias Primarias Múltiples/metabolismo , Ácido Oxónico/efectos adversos , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/metabolismo , Pancrelipasa/uso terapéutico , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas p21(ras) , Neoplasias Gástricas/genética , Neoplasias Gástricas/metabolismo , Tegafur/efectos adversos , Resultado del Tratamiento , Proteínas ras/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...